NovavaxNVAX
NVAX
About: Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
Employees: 1,992
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
24% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 34
10% more capital invested
Capital invested by funds: $1.08B [Q2] → $1.19B (+$104M) [Q3]
4% more funds holding
Funds holding: 224 [Q2] → 232 (+8) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
0% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 64
2.11% less ownership
Funds ownership: 60.66% [Q2] → 58.55% (-2.11%) [Q3]
25% less call options, than puts
Call options by funds: $124M | Put options by funds: $164M
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$19
118%
upside
Avg. target
$23
168%
upside
High target
$26
199%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Vernon Bernardino 32% 1-year accuracy 19 / 59 met price target | 118%upside $19 | Buy Reiterated | 10 Dec 2024 |
Jefferies Roger Song 19% 1-year accuracy 3 / 16 met price target | 187%upside $25 | Buy Maintained | 16 Oct 2024 |
B. Riley Securities Mayank Mamtani 35% 1-year accuracy 8 / 23 met price target | 199%upside $26 | Buy Reiterated | 10 Oct 2024 |
Financial journalist opinion
Based on 13 articles about NVAX published over the past 30 days
Neutral
PRNewsWire
1 week ago
Novavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First $50 Million Milestone
Novavax continues to progress Sanofi agreement by achieving first milestone, with additional milestones and ongoing tiered royalties to come, solidifying a strong model for future partnerships Novavax's COVID-19 vaccine included in Sanofi's two combination vaccine candidates for prevention of influenza and COVID-19, for which Phase 1/2 trials were initiated and Fast Track designation recently granted in the U.S. GAITHERSBURG, Md. , Dec. 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress in Q4 2024 advancing its corporate growth strategy through its partnership with Sanofi.
Positive
Zacks Investment Research
1 week ago
Why Is Novavax (NVAX) Up 13.6% Since Last Earnings Report?
Novavax (NVAX) reported earnings 30 days ago. What's next for the stock?
Positive
Zacks Investment Research
1 week ago
NVAX Starts Late-Stage Study on COVID-19-Flu Combo & Flu Vaccines
Novavax is working with the FDA to explore a pathway for accelerated approval of the COVID-19-flu combination and standalone flu vaccines.
Positive
Zacks Investment Research
1 week ago
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Neutral
PRNewsWire
1 week ago
Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza
Company continuing to work with the U.S. FDA on potential for accelerated approval pathway Novavax intends to partner on both candidates to advance to filing and commercialization GAITHERSBURG, Md. , Dec. 10, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the first participants have been dosed in its COVID-19-Influenza Combination (CIC) and stand-alone seasonal influenza Phase 3 trial.
Positive
The Motley Fool
2 weeks ago
2 Beaten-Down "Pandemic Stocks" to Consider for Contrarian Investors
Many companies that performed well in the early pandemic years have since fallen off the radar or at least have seen their shares drop substantially during the past three years. Telemedicine Teladoc Health (TDOC 0.64%) and vaccine maker Novavax (NVAX -1.31%) belong in this group: Both have significantly lagged behind the market since 2021.
Positive
Reuters
2 weeks ago
Novavax to sell Czech manufacturing unit to Novo Nordisk for $200 mln
COVID-19 vaccine maker Novavax said on Wednesday it will sell its manufacturing facility in Czech Republic to Wegovy-maker Novo Nordisk for $200 million and use the proceeds for its vaccine pipeline.
Neutral
PRNewsWire
2 weeks ago
Novavax Announces Sale of Czech Republic Manufacturing Site to Novo Nordisk for $200 Million
Agreement provides significant, non-dilutive capital to Novavax, further enabling the Company to advance its corporate growth strategy of driving value from its pipeline assets and proven technology platform Provides Novavax with $190 million cash payment in 2024 and additional $10 million in 2025, and annual operating cost reductions of approximately $80 million GAITHERSBURG, Md. , Dec. 4, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it has signed a definitive agreement to sell its manufacturing facility in Bohumil, Czech Republic to Novo Nordisk for $200 million.
Positive
Zacks Investment Research
3 weeks ago
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
Neutral
Accesswire
3 weeks ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX
NEW YORK, NY / ACCESSWIRE / November 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or the "Company") (NASDAQ:NVAX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Charts implemented using Lightweight Charts™